cbdMD (YCBD) Profit After Tax Growth (3y) (2019 - 2026)
cbdMD (YCBD) Profit After Tax Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 14.01% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.89% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 15.37% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | 13.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.97% |
| Dec 31, 2025 | 58.48% |
| Sep 30, 2025 | 64.05% |
| Jun 30, 2025 | 69.53% |
| Mar 31, 2025 | 53.09% |
| Dec 31, 2024 | 26.01% |
| Sep 30, 2024 | 63.04% |
| Jun 30, 2024 | -33.13% |
| Mar 31, 2024 | 37.80% |
| Dec 31, 2023 | 52.66% |
| Sep 30, 2023 | -38.37% |
| Jun 30, 2023 | 41.74% |
| Mar 31, 2023 | -27.85% |
| Dec 31, 2022 | -32.11% |
| Sep 30, 2022 | -30.67% |
| Jun 30, 2022 | -5.51% |
| Dec 31, 2021 | -106.36% |
| Sep 30, 2021 | -97.67% |
| Jun 30, 2021 | 39.58% |
| Mar 31, 2021 | -109.11% |